The antitumor activity study of ginsenosides and metabolites in lung cancer cell

American Journal of Translational Research

Volumn 8, Issue 4, 2016, Pages 1708-1718

  Xu, Feng Yuan ^a,b   Shang, Wen Qing ^c   Yu, Jia Jun ^c   Sun, Qian ^d   Li, Ming Qing ^c,e   Sun, Jian Song ^a  

^a JIANGXI NORMAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d EMORY UNIVERSITY   (United States)

^e FUDAN UNIVERSITY   (China)

Author keywords

Antitumor activity; Ginsenosides; Lung cancer cell; PPD; PPT

Indexed keywords

CISPLATIN; GINSENOSIDE; GINSENOSIDE RG 3; GINSENOSIDE RH 2; PROTOPANAXADIOL; PROTOPANAXATRIOL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; CELL COUNTING; CELL INVASION; CELL INVASION ASSAY; CELL VIABILITY; CELL VIABILITY ASSAY; CONTROLLED STUDY; HUMAN; HUMAN CELL; LUNG CANCER;

EID: 84964843593     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Nag SA, Qin JJ, Wan W, Wang MH, Wang H and Zhang R. Ginsenosides as anticancer agents: in vitro and in vivo activities, structure-activity relationships, and molecular mechanisms of action. Front Pharmacol 2012; 3: 25
2. Hann CL and Rudin CM. Management of smallcell lung cancer: incremental changes but hope for the future. Oncology (Williston Park) 2008; 22: 1486-1492
3. Burdett S, Stephens R, Stewart L, Tierney J, Auperin A, Le Chevalier T, Le Pechoux C, Pignon JP, Arriagada R, Higgins J, Johnson D, van Meerbeeck J, Parmar M, Souhami R, Bell D, Cartei G, Cormier Y, Cullen M, Ganz P, Gridelli C, Kaasa S, Quoix E, Rapp E, Seymour L, Spiro S, Thatcher N, Tummarello D, Williams C, and Williamson I. Chemotherapy in Addition to Supportive Care Improves Survival in Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 16 Randomized Controlled Trials. J Clin Oncol 2008; 26: 4617-4625
4. Murray N and Turrisi AT. A review of first-line treatment for small-cell lung cancer. J Thorac Oncol 2006; 1: 270-278
5. Johnson TE, Hermanson D, Wang L, Kassie F, Upadhyaya P, O’Sullivan MG, Hecht SS, Lu J and Xing C. Lung tumorigenesis suppressing effects of a commercial kava extract and its selected compounds in A/J mice. Am J Chin Med 2011; 39: 727-742
6. Christensen LP. Ginsenosides chemistry, biosynthesis, analysis, and potential health effects. Adv Food Nutr Res 2009; 55: 1-99
7. De Smet PA. Herbal remedies. N Engl J Med 2002; 347: 2046-2056
8. Qi LW, Wang CZ and Yuan CS. American ginseng: potential structure-function relationship in cancer chemoprevention. Biochem Pharmacol 2010; 80: 947-954
9. Iishi H, Tatsuta M, Baba M, Uehara H, Nakaizumi A, Shinkai K, Akedo H, Funai H, Ishiguro S and Kitagawa I. Inhibition by ginsenoside Rg3 of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in Wistar rats. Clin Exp Metastasis 1997; 15: 603-611
10. Shinkai K, Akedo H, Mukai M, Imamura F, Isoai A, Kobayashi M and Kitagawa I. Inhibition of in vitro tumor cell invasion by ginsenoside Rg3. Jpn J Cancer Res 1996; 87: 357-362
11. Xu TM, Xin Y, Cui MH, Jang X and Gu LP. Inhibitory effect of ginsenoside Rg3 combined with cyclophosphamide on growth and angiogenesis of ovarian cancer. Chin Med J (Engl) 2007; 120: 584-588
12. Zhang Q, Kang X, and Zhao W. Antiangiogenic effect of low-dose cyclophosphamide combined with ginsenoside Rg3 on Lewis lung carcinoma. Biochem Biophys Res Commun 2006; 342: 824-828
13. Yue PY, Wong DY, Wu PK, Leung PY, Mak NK, Yeung HW, Liu L, Cai Z, Jiang ZH, Fan TP and Wong RN. The angiosuppressive effects of 20(R)-ginsenoside Rg3. Biochem Pharmacol 2006; 72: 437-445
14. Chen J, Peng H, Ou-Yang X and He X. Research on the antitumor effect of ginsenoside Rg3 in B16 melanoma cells. Melanoma Res 2008; 18: 322-329
15. Qian T, Cai Z, Wong RN, Mak NK and Jiang ZH. In vivo rat metabolism and pharmacokinetic studies of ginsenoside Rg3. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 816: 223-232
16. Shibata S. Chemistry and cancer preventing activities of ginseng saponins and some related triterpenoid compounds. J Korean Med Sci 2001; Suppl 16: S28-S37
17. Bi WY, Fu BD, Shen HQ, Wei Q, Zhang C, Song Z, Qin QQ, Li HP, Lv S, Wu SC, Yi PF and Wei XB. Sulfated derivative of 20(S)-ginsenoside Rh2 inhibits inflammatory cytokines through MAPKs and NF-kappa B pathways in LPS-induced RAW264.7 macrophages. Inflammation 2012; 35: 1659-1668
18. He L, Lee J, Jang JH, Lee SH, Nan MH, Oh BC, Lee SG, Kim HH, Soung NK, Ahn JS and Kim BY. Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-kappaB, NFATc1 and c-Fos. Bone 2012; 50: 1207-1213
19. Luo JZ and Luo L. Ginseng on hyperglycemia: effects and mechanisms. Evid Based Complement Alternat Med 2009; 6: 423-427
20. Wu N, Wu GC, Hu R, Li M and Feng H. Ginsenoside Rh2 inhibits glioma cell proliferation by targeting microRNA-128. Acta Pharmacol Sin 2011; 32: 345-353
21. Li B, Zhao J, Wang CZ, Searle J, He TC, Yuan CS and Du W. Ginsenoside Rh2 induces apoptosis and paraptosis-like cell death in colorectal cancer cells through activation of p53. Cancer Lett 2011; 301: 185-192
22. Zhu GY, Li YW, Tse AK, Hau DK, Leung CH, Yu ZL and Fong WF. 20(S)-Protopanaxadiol, a metabolite of ginsenosides, induced cell apoptosis through endoplasmic reticulum stress in human hepatocarcinoma HepG2 cells. Eur J Pharmacol 2011; 668: 88-98
23. Wang W, Rayburn ER, Hao M, Zhao Y, Hill DL, Zhang R and Wang H. Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides. Prostate 2008; 68: 809-819
24. Li MQ, Hou XF, Shao J, Tang CL, and Li DJ. The DSCs-expressed CD82 controls the invasiveness of trophoblast cells via integrinbeta1/ MAPK/MAPK3/1 signaling pathway in human first-trimester pregnancy. Biol Reprod 2010; 82: 968-979
25. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E and Thun MJ. Cancer Statistics, 2003. CA Cancer J Clin 2003; 53: 5-26
26. American Cancer Society. Cancer Facts and Figures, 2015
27. Christensen LP. Ginsenosides chemistry, biosynthesis, analysis, and potential health effects. Adv Food Nutr Res 2009; 55: 1-99
28. Chang YS, Seo EK, Gyllenhaal C and Block KI. Panax ginseng: a role in cancer therapy? Integr Cancer Ther 2003; 2: 13-33
29. Attele AS, Wu JA and Yuan CS. Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 1999; 58: 1685-1693
30. Kitts DD and Hu C. Efficacy and safety of ginseng. Pub Health Nut 2000; 3: 473-485
31. Jung JS, Ahn JH, Le TK, Kim DH and Kim HS. Protopanaxatriol ginsenoside Rh1 inhibits the expression of matrix metalloproteinases and the in vitro invasion/migration of human astroglioma cells. Neurochem Int 2013; 63: 80-86
32. Jung SH, Woo MS, Kim SY, Kim WK, Hyun JW, Kim EJ, Kim DH and Kim HS. Ginseng saponin metabolite suppresses phorbol ester-induced matrix metalloproteinase-9 expression through inhibition of activator protein-1 and mitogenactivated protein kinase signaling pathways in human astroglioma cells. Int J Cancer 2006; 118: 490-497
33. Antler AS, Ough Y, Pitchumoni CS, Davidian M and Thelmo W. Gastrointestinal metastases from malignant tumors of the lung. Cancer 1982; 49: 170-172
34. McNeill PM, Wagman LD and Neifeld JP. Small bowel metastases from primary carcinoma of the lung. Cancer 1987; 59:1486-1489
35. Stenbygaard LE and Sorensen JB. Small bowel metastases in non-small cell lung cancer. Lung Cancer 1999; 26: 95-101
36. Liu T, Zhao L, Zhang Y, Chen W, Liu D, Hou H, Ding L and Li X. Ginsenoside 20(S)-Rg3 targets HIF-1α to block hypoxia-induced epithelialmesenchymal transition in ovarian cancer cells. PLoS One 2014; 9: e103887
37. Lee YJ, Lee S, Ho JN, Byun SS, Hong SK, Lee SE and Lee E. Synergistic antitumor effect of ginsenoside Rg3 and cisplatin in cisplatinresistant bladder tumor cell line. Oncol Rep 2014; 32: 1803-1808
38. Li L, Wang Y, Qi B, Yuan D, Dong S, Guo D, Zhang C and Yu M. Suppression of PMA-induced tumor cell invasion and migration by ginsenoside Rg1 via the inhibition of NF-κBdependent MMP-9 expression. Oncol Rep 2014; 32: 1779-1786
39. Shi Q, Li J, Feng Z, Zhao L, Luo L, You Z, Li D, Xia J, Zuo G and Chen D. Effect of ginsenoside Rh2 on the migratory ability of HepG2 liver carcinoma cells: recruiting histone deacetylase and inhibiting activator protein 1 transcription factors. Mol Med Rep 2014; 10: 1779-1785
40. Xu QF, Fang XL and Chen DF. Pharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats. J Ethnopharmacol 2003; 84: 187-192
41. Joo KM, Lee JH, Jeon HY, Park CW, Hong DK, Jeong HJ, Lee SJ, Lee SY and Lim KM. Pharmacokinetic study of ginsenoside Re with pure ginsenoside Re and ginseng berry extracts in mouse using ultra performance liquid chromatography/ mass spectrometric method. J Pharm Biomed Anal 2010; 51: 278-283
42. Liu H, Yang J, Du F, Gao X, Ma X, Huang Y, Xu F, Niu W, Wang F, Mao Y, Sun Y, Lu T, Liu C, Zhang B and Li C. Absorption and disposition of ginsenosides after oral administration of Panax notoginseng extract to rats. Drug Metab Dispos 2009; 37: 2290-2298.